# US 5,703,045 A · Treating disorders by application of insulin-like growth factors and analogs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,703,045 A
- Document ID: US5703045A
- Status: Granted
- Kind: A
- Application number: 08/462,018
- Filed: 1995-06-05
- Granted: 1997-12-30
- Earliest claimed: 1989-06-05
- Assignees: Cephalon, Inc.
- Inventors: Michael E. Lewis; James C. Kauer; Kevin R. Smith; Kathleen V. Callison; Frank Baldino; Nicola Neff; Mohamed Iqbal
- Web page: https://patentgrep.com/patent/US5703045A

## CPC

- A61K 38/30: Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 {(insulin-like growth factor binding protein A61K38/1754)}
- A61P 25/00: Drugs for disorders of the nervous system
- C07K 14/65: Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A method of enhancing the survival of neuronal cells in a mammal, the cells being at risk of dying, the method comprising administering to the mammal an effective amount of at least one of the following substances: IGF-I; a functional derivative of IGF-I; IGF-II; a functional derivative of IGF-II; IGF-III; or a functional derivative of IGF-III.

## Claims

### Claim 1

A method of enhancing the survival of non-mitotic neuronal cells of the brain or spinal cord of a mammal, said cells being at risk of dying due to the effects of a neurological disease, head trauma or spinal cord injury on said neuronal cells, said method comprising administering to said mammal an effective amount of insulin-like growth factor-II.

### Claim 2 (depends on 1)

The method of claim 1, wherein said neuronal cells are cholinergic cells .